Injectable Opioid Treatment in England Clinical Experience Rob van der Waal.

Slides:



Advertisements
Similar presentations
1 setting standards for prescribing Dr Keron Fletcher.
Advertisements

Originally developed by Susan Warman, BN., Helen Gourlay,BN/MN.,and Janet Walker, BN. January 1997 Revised Dec 2005 by Nancy Schuttenbeld -Acute Pain Nurse.
Education and Training Module for Ohio EMS Developed in the 1960s Opioid antagonist Emergent overdose treatment in the hospital and prehospital settings.
Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
Lecture 4.
1 Co-occurring Alcohol and Other Drug and Mental Health Conditions in Alcohol and other Drug Treatment Settings Session 4: Management and Treatment.
SBAR Situation Background Assessment Recommendation
Copyright © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 05: Relieving Pain and Providing Comfort.
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
MEDICATION SAFETY: Clozapine Initiation Chart Review
Drug and Therapeutics Committee Session 7A. Identifying Problems with Medicine Use: Indicator Studies.
Module 6: Routine HIV Testing of TB Patients. Learning Objectives Explain why TB suspects and patients should be routinely tested for HIV Summarize the.
Pain Agitation & Delirium SCCM Pain assessment i. We recommend that pain be routinely monitored in all adult ICU patients (+1B). ii. The Behavioral.
Practice Guidelines for the Prevention, Detection, and Management of Respiratory Depression Associated with Neuraxial Opioid Administration Troy Tada,
Pain management for AKT NICE guidelines: Neuropathic pain Opioid conversion Controlled drugs.
Oral Care for Patients at Risk for Ventilator-Associated Pneumonia Issued April 2010.
Medicines and drugs Option D Part 1.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Recommendations on the Management of Opioid Overdose Ruth Birgin.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
Good Prescribing to support Criminal Justice Interventions
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
OPIOID SUBSTITUTION THERAPY
Current Trends In Identifying And Treating Newborns With Withdrawal Syndromes 6/24/2010.
FIVE MINUTES TO MAKE A DIFFERENCE Presentation by: Mark Barnes.
2009 Pandemic Education Package Pharmacology Review.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
An approach to maintenance Benzodiazepine prescribing Dr Malcolm Bruce Consultant Psychiatrist in Addiction NHS Lothian
Allegheny County Overdose Prevention Coalition
Chapter 8 Narcotics. Historical Perspectives The term narcotics is from the Greek word meaning stupor Throughout history opium figured prominently in.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Introduction to Pharmacology. ORIENTATION TO PHARMACOLOGY Objectives: 1. Definition of the four basic terms (drug, pharmacology, clinical pharmacology,
Pre-Operative and Post-Operative Care
Perioperative Nursing Care
Breakthrough, emergency, and incident pain
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
Clinical Management Course: Medical Complications of Alcoholism Peter R. Martin, M.D. Professor of Psychiatry and Pharmacology.
Buprenorphine {Suboxone®, Subutex®}
UCLA Brain Institute Outreach Adrina Kocharian and Rachel Oseas.
Detox workshop Susanna Lawrence October Aim and objectives  Create consistent, evidence based process for opiate, alcohol and benzodiazepine detoxes.
$1 Million $500,000 $250,000 $125,000 $64,000 $32,000 $16,000 $8,000 $4,000 $2,000 $1,000 $500 $300 $200 $100 Welcome.
Innovation and excellence in health and care Addenbrooke’s Hospital I Rosie Hospital FY1 Introduction to Palliative Care 7 th August 2015 Clinical Nurse.
Medicines that interact with alcohol See “Guidance on the administration of medicines to inpatients believed to have consumed alcohol ”
Opioids Tapering Melissa B. Weimer, DO, MCR. Disclosures Dr. Weimer is a consultant for INFORMed, IMPACT education, and the American Association of Addiction.
A DAY IN THE LIFE OF BOOTS QUEEN STREET STATION Lynda Allan Store Manager.
Prepared by Dr. Ramin Safakish, MD, FRCPC – March 2016.
The recovery agenda – a pharmacy perspective
Current Concepts in Pain Management
WITHDRAWING NIV AT THE END OF LIFE IN MOTOR NEURONE DISEASE
Psychiatric Treatment
What does pharmacology have to do with treatment of heroin addiction?
Special Populations: Opioids and OB Patients(1)
Emergency Care Part 3: Surgery in Children with Diabetes
Hospice in Hospital - GIP and Beyond
2.13 Copyright UKCS #
Introduction to Clinical Pharmacology Chapter 16 Opioid Antagonists
Pain Management: Patients Maintained on Buprenorphine
Re-bundling Medically Assisted Treatment
Background Cancers are among the leading causes of morbidity and mortality worldwide, responsible for 18.1 million new cases and 9.6 million deaths in.
1st Line Medication Lorazepam 0.5 mg p.o/i.m
Opioid prescribing workflow in the electronic medical record.
Sarah Gregory Diabetes Specialist Nurse Diabetes UK Clinical Champion
Emergency Care Part 3: Surgery in Children with Diabetes
Guideline for the Treatment of Alcohol Use Disorder in the Outpatient Setting with Intramuscular Naltrexone Assess Candidacy for IM Naltrexone Meets DMS-V.
Introduction to Clinical Pharmacology Chapter 16 Opioid Antagonists
Substance Use Teaching Project (SUTP) “Action Plan” Introduction
Medication Assisted Treatment of Opioid Use Disorder
PALLIATIVE CARE FOR COPD PATIENTS:
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Injectable Opioid Treatment in England Clinical Experience Rob van der Waal

The basics (1) F All Injectable diamorphine/ methadone administered under supervision F Oral supplement is necessary to ensure stability over 24 hours (take home available) 3Oral Methadone 3Slow Release Oral Morphine 3Buprenorphine

The basics (2) F Open all days, AM and PM sessions F Flexible dosing regimes available – converting Injectable to oral (partly or completely) 3To minimize the inconvenience of IOT 3To encourage patient choice 3To provide exit route

Assessment and Introduction to IOT F Establishing eligibility and feasibility F Trial period on oral medication followed by partial conversion to Injectables F Gradual titration of Injectable component and oral component! until patient is comfortable F Monitor and – if possible - manage problems (e.g. alcohol/ benzodiazepine use, injecting sites)

Stabilisation F Reduction/ cessation of street heroin use F Reduction/cessation of other street drug use F Develop safe injecting routine (site rotation etc) F Medium-long term care planning F If not successful patients move back to standard oral maintenance treatment

Medium – long term F Reduce/stop other street drug use F Reduction of injecting frequency and attendance F Increased focus on health and socio economic aspects in care planning F Exit or long term maintenance?

Flexible Dosing Example F Option ADiamorphine 200mg IV am Diamorphine 200mg IV pm Methadone oral 30mg F Option BDiamorphine 200mg IV / day Methadone oral 100mg F Option CMethadone oral 170mg

Monitoring pre and post dose F Routine – brief observation to establish 3if it is safe to proceed 3If there are complications post dose F Comprehensive - involves intermittent assessment of 3 vital signs (including pulse oximetry) 3 breath alcohol levels 3 UDS dipstick 3 rating of withdrawal/ sedation levels

Injecting F Hygiene Washing of hands, cleaning of sites before and after injection F Injecting sites Peripheral veins, muscles, no active inflammation F Injecting time Approximately 5 minutes once routine has been established

Injecting Problems and solutions F Poor veins limit intravenous injecting (IV) 3deep veins (e.g. groin) not allowed F Single site IM injecting (painful, infections) F The majority of patients now inject intra muscular (IM) or subcutaneously (SC) F And are required to rotate sites

Monitoring Problems F Severe post dose sedation related to 3Benzodiazepine use Not always evident prior to dosing 3Alcohol use 3Respiratory illness F It is easy to monitor alcohol use but benzodiazepine use is more costly, labor intensive and requires the patient to provide a urine specimen on the spot 3serious risk that can require immediate intervention (e.g. observation, oxygen naloxone)

Co morbidity F Due to daily attendance the clinic offers an excellent opportunity to administer other medication under supervision, for example when thee are concern about compliance F E.g. antidepressants, antipsychotics, mood stabilisers

Summary (1) F Diamorphine can be sufficiently rewarding to keep patients engaged in highly structured treatment F Structure (protocol, ritual) is a critical therapeutic component F Patients have made significant progress, some have moved back to standard oral treatment and have maintained the benefits

Summary (2) F When not successful, it is often due to other drug use (e.g. alcohol, poly drug use), health, socio- economic factors or simply because of patient choice F Resolving the above appears conditional to long term success